Profilaxia pós-exposição (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Profilaxia pós-exposição" in Portuguese language version.

refsWebsite

Global rank Portuguese rank

14cdc.gov

218^th place

177^th place

10nih.gov

4^th place

8^th place

10doi.org

2^nd place

4^th place

3web.archive.org

1^st place

2who.int

195^th place

150^th place

1sermais.pt

low place

1harvard.edu

18^th place

51^st place

1britannica.com

40^th place

17^th place

1semanticscholar.org

11^th place

968^th place

1zenodo.org

621^st place

1,847^th place

1hrsa.gov

low place

1uhb.nhs.uk

low place

1worldcat.org

5^th place

britannica.com

global.britannica.com

"tetanus" in the Encyclopædia Britannica. Last Updated 7-17-2013

cdc.gov

«Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016» (PDF). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Consultado em 24 de junho de 2016
«Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016» (PDF). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Consultado em 24 de junho de 2016
«Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016» (PDF). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Consultado em 24 de junho de 2016
«Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016» (PDF). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Consultado em 24 de junho de 2016
«Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016» (PDF). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Consultado em 24 de junho de 2016
«Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016» (PDF). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Consultado em 24 de junho de 2016
«Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016» (PDF). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Consultado em 24 de junho de 2016
Smith, Dawn K.; Grohskopf, Lisa A.; Black, Roberta J.; Auerbach, Judith D.; Veronese, Fulvia; Struble, Kimberly A. (21 de janeiro de 2005). «Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States». cdc.gov. Centers for Disease Control. Consultado em 7 de julho de 2011
Smith, Dawn K.; Grohskopf, Lisa A.; Black, Roberta J.; Auerbach, Judith D.; Veronese, Fulvia; Struble, Kimberly A. (21 de janeiro de 2005). «Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States». cdc.gov. Centers for Disease Control. Consultado em 7 de julho de 2011
Smith, Dawn K.; Grohskopf, Lisa A.; Black, Roberta J.; Auerbach, Judith D.; Veronese, Fulvia; Struble, Kimberly A. (21 de janeiro de 2005). «Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States». cdc.gov. Centers for Disease Control. Consultado em 7 de julho de 2011
«Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016» (PDF). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Consultado em 24 de junho de 2016
Smith, Dawn K.; Grohskopf, Lisa A.; Black, Roberta J.; Auerbach, Judith D.; Veronese, Fulvia; Struble, Kimberly A. (21 de janeiro de 2005). «Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States». cdc.gov. Centers for Disease Control. Consultado em 7 de julho de 2011
«Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016» (PDF). Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Consultado em 24 de junho de 2016
«Hepatitis A Questions and Answers for Health Professionals». CDC. 9 de novembro de 2018. Consultado em 9 de dezembro de 2018

doi.org

dx.doi.org

Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, Kieny MP, Lathe R, Lecocq JP, Mackett M (1984). «Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene». Proc. Natl. Acad. Sci. U.S.A. 81 (22): 7194–8. Bibcode:1984PNAS...81.7194W. PMC 392104. PMID 6095272. doi:10.1073/pnas.81.22.7194
Cardo, D. M.; Culver, D. H.; Ciesielski, C. A.; Srivastava, P. U.; Marcus, R.; Abiteboul, D.; Heptonstall, J.; Ippolito, G.; Lot, F.; McKibben, P. S.; Bell, D. M. (1997). «A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure». New England Journal of Medicine. 337 (21): 1485–1490. PMID 9366579. doi:10.1056/NEJM199711203372101
Shih, CC; Kaneshima, H; Rabin, L; Namikawa, R; Sager, P; McGowan, J; McCune, JM (março de 1991). «Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner.». The Journal of Infectious Diseases. 163 (3): 625–7. PMID 1995734. doi:10.1093/infdis/163.3.625
Connor, EM; Sperling, RS; Gelber, R; Kiselev, P; Scott, G; O'Sullivan, MJ; VanDyke, R; Bey, M; Shearer, W; Jacobson, RL (3 de novembro de 1994). «Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.». The New England Journal of Medicine. 331 (18): 1173–80. PMID 7935654. doi:10.1056/NEJM199411033311801
Watts, DH (13 de junho de 2002). «Management of human immunodeficiency virus infection in pregnancy.». The New England Journal of Medicine. 346 (24): 1879–91. PMID 12063373. doi:10.1056/NEJMra013338
Katz, M. H.; Gerberding, J. L. (1997). «Postexposure Treatment of People Exposed to the Human Immunodeficiency Virus through Sexual Contact or Injection-Drug Use». New England Journal of Medicine. 336 (15): 1097–1100. PMID 9091810. doi:10.1056/NEJM199704103361512
Kuhar, David T.; Henderson, David K.; Struble, Kimberly A.; Heneine, Walid; Thomas, Vasavi; Cheever, Laura W.; Gomaa, Ahmed; Panlilio, Adelisa L. (2013). «Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis». Infection Control and Hospital Epidemiology. 34 (9): 875–892. PMID 23917901. doi:10.1086/672271
Desai, Monica; Field, Nigel; Grant, Robert; McCormack, Sheena (11 de dezembro de 2017). «State of the art review: Recent advances in PrEP for HIV». BMJ (Clinical Research Ed.). 359: j5011. PMC 6020995. PMID 29229609. doi:10.1136/bmj.j5011
Diprose, P; Deakin, C.D.; Smedley, J (2000). «Ignorance of post-exposure prophylaxis guidelines following HIV needlestick injury may increase the risk of seroconversion». British Journal of Anaesthesia. 84 (6): 767–770. PMID 10895754. doi:10.1093/oxfordjournals.bja.a013591
CDC (14 de setembro de 2017). «Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis». MMWR. Morbidity and Mortality Weekly Report. 66 (36): 959–960. ISSN 0149-2195. PMC 5657912. PMID 28910270. doi:10.15585/mmwr.mm6636a5. eISSN 1545-861X

harvard.edu

ui.adsabs.harvard.edu

Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, Kieny MP, Lathe R, Lecocq JP, Mackett M (1984). «Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene». Proc. Natl. Acad. Sci. U.S.A. 81 (22): 7194–8. Bibcode:1984PNAS...81.7194W. PMC 392104. PMID 6095272. doi:10.1073/pnas.81.22.7194

hrsa.gov

hab.hrsa.gov

«HIV/AIDS Bureau - HIV Care Pocket Guide 2006 - Occupational HIV Postexposure Prophylaxis (PEP)». Consultado em 5 de março de 2008. Cópia arquivada em 11 de março de 2008

nih.gov

ncbi.nlm.nih.gov

Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, Kieny MP, Lathe R, Lecocq JP, Mackett M (1984). «Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene». Proc. Natl. Acad. Sci. U.S.A. 81 (22): 7194–8. Bibcode:1984PNAS...81.7194W. PMC 392104. PMID 6095272. doi:10.1073/pnas.81.22.7194
Cardo, D. M.; Culver, D. H.; Ciesielski, C. A.; Srivastava, P. U.; Marcus, R.; Abiteboul, D.; Heptonstall, J.; Ippolito, G.; Lot, F.; McKibben, P. S.; Bell, D. M. (1997). «A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure». New England Journal of Medicine. 337 (21): 1485–1490. PMID 9366579. doi:10.1056/NEJM199711203372101
Shih, CC; Kaneshima, H; Rabin, L; Namikawa, R; Sager, P; McGowan, J; McCune, JM (março de 1991). «Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner.». The Journal of Infectious Diseases. 163 (3): 625–7. PMID 1995734. doi:10.1093/infdis/163.3.625
Connor, EM; Sperling, RS; Gelber, R; Kiselev, P; Scott, G; O'Sullivan, MJ; VanDyke, R; Bey, M; Shearer, W; Jacobson, RL (3 de novembro de 1994). «Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.». The New England Journal of Medicine. 331 (18): 1173–80. PMID 7935654. doi:10.1056/NEJM199411033311801
Watts, DH (13 de junho de 2002). «Management of human immunodeficiency virus infection in pregnancy.». The New England Journal of Medicine. 346 (24): 1879–91. PMID 12063373. doi:10.1056/NEJMra013338
Katz, M. H.; Gerberding, J. L. (1997). «Postexposure Treatment of People Exposed to the Human Immunodeficiency Virus through Sexual Contact or Injection-Drug Use». New England Journal of Medicine. 336 (15): 1097–1100. PMID 9091810. doi:10.1056/NEJM199704103361512
Kuhar, David T.; Henderson, David K.; Struble, Kimberly A.; Heneine, Walid; Thomas, Vasavi; Cheever, Laura W.; Gomaa, Ahmed; Panlilio, Adelisa L. (2013). «Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis». Infection Control and Hospital Epidemiology. 34 (9): 875–892. PMID 23917901. doi:10.1086/672271
Desai, Monica; Field, Nigel; Grant, Robert; McCormack, Sheena (11 de dezembro de 2017). «State of the art review: Recent advances in PrEP for HIV». BMJ (Clinical Research Ed.). 359: j5011. PMC 6020995. PMID 29229609. doi:10.1136/bmj.j5011
Diprose, P; Deakin, C.D.; Smedley, J (2000). «Ignorance of post-exposure prophylaxis guidelines following HIV needlestick injury may increase the risk of seroconversion». British Journal of Anaesthesia. 84 (6): 767–770. PMID 10895754. doi:10.1093/oxfordjournals.bja.a013591
CDC (14 de setembro de 2017). «Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis». MMWR. Morbidity and Mortality Weekly Report. 66 (36): 959–960. ISSN 0149-2195. PMC 5657912. PMID 28910270. doi:10.15585/mmwr.mm6636a5. eISSN 1545-861X

semanticscholar.org

Connor, EM; Sperling, RS; Gelber, R; Kiselev, P; Scott, G; O'Sullivan, MJ; VanDyke, R; Bey, M; Shearer, W; Jacobson, RL (3 de novembro de 1994). «Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.». The New England Journal of Medicine. 331 (18): 1173–80. PMID 7935654. doi:10.1056/NEJM199411033311801

sermais.pt

Associação Portuguesa para a Prevenção e Desafio à SIDA. «Profilaxia pós-exposição». Consultado em 20 de outubro de 2013

uhb.nhs.uk

«Archived copy» (PDF). Consultado em 7 de junho de 2021. Cópia arquivada (PDF) em 7 de junho de 2021

web.archive.org

«Rabies: Guide for post-exposure prophylaxis». World Health Organization. Consultado em 28 de maio de 2013. Cópia arquivada em 27 de junho de 2004
«HIV/AIDS Bureau - HIV Care Pocket Guide 2006 - Occupational HIV Postexposure Prophylaxis (PEP)». Consultado em 5 de março de 2008. Cópia arquivada em 11 de março de 2008
«Archived copy» (PDF). Consultado em 7 de junho de 2021. Cópia arquivada (PDF) em 7 de junho de 2021

who.int

«Rabies». www.who.int. World Health Organization
«Rabies: Guide for post-exposure prophylaxis». World Health Organization. Consultado em 28 de maio de 2013. Cópia arquivada em 27 de junho de 2004

worldcat.org

CDC (14 de setembro de 2017). «Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis». MMWR. Morbidity and Mortality Weekly Report. 66 (36): 959–960. ISSN 0149-2195. PMC 5657912. PMID 28910270. doi:10.15585/mmwr.mm6636a5. eISSN 1545-861X

zenodo.org

Kuhar, David T.; Henderson, David K.; Struble, Kimberly A.; Heneine, Walid; Thomas, Vasavi; Cheever, Laura W.; Gomaa, Ahmed; Panlilio, Adelisa L. (2013). «Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis». Infection Control and Hospital Epidemiology. 34 (9): 875–892. PMID 23917901. doi:10.1086/672271